Microdosing involves taking roughly one-tenth to one-twentieth of a full psychedelic dose, small enough that you shouldn’t feel any obvious shift in perception, mood, or consciousness. The goal is to stay below the threshold of a noticeable “trip” while still nudging brain chemistry in ways that may improve mood, creativity, or focus over time. The practice has exploded in popularity, but the science behind it is still catching up to the hype, and what we know so far is a complicated mix of promising biology, strong placebo effects, and real safety questions.
What Happens in Your Brain
The two most common substances people microdose are psilocybin (from mushrooms) and LSD. Both work primarily by binding to a specific serotonin receptor called 5-HT2A. Serotonin is one of the brain’s key chemical messengers, involved in mood regulation, learning, and perception. When psilocybin or LSD locks onto 5-HT2A receptors, it triggers a cascade of effects that look different from what your own serotonin normally does.
The most interesting downstream effect is neuroplasticity, your brain’s ability to rewire and form new connections. Even a single dose of psilocybin has been shown to increase the expression of genes related to brain growth and adaptation, including one called BDNF (brain-derived neurotrophic factor), which acts like fertilizer for neurons. In animal studies, this translates into measurable physical changes: denser, more complex branching on neurons in the hippocampus (involved in memory and emotion) and the frontal cortex (involved in decision-making and focus). These structural changes have been detected up to a week after a single dose.
In stressed animals, psilocybin has been shown to rescue deficits in brain structure, restoring spine density on neurons, boosting growth-factor levels, and promoting the birth of new brain cells, all while reducing fear-related behavior. The theory behind microdosing is that repeated sub-perceptual doses could gently promote these same neuroplastic changes over weeks or months, without the intense altered states that come with a full dose.
Network-Level Changes
At full doses, psychedelics produce a well-documented shift in how brain networks communicate. Your brain normally operates with distinct networks that stay mostly separate: the default mode network (active during daydreaming, self-reflection, and mind-wandering), sensory networks, and executive networks. Full-dose psychedelics consistently reduce connectivity within the default mode network while increasing communication between networks that don’t usually talk to each other. The result is a brain that temporarily moves from a compartmentalized state to a more globally interconnected one.
This is thought to underlie the feelings of ego dissolution, creative insight, and emotional breakthroughs people report during psychedelic experiences. The key caveat for microdosing: there is currently no direct evidence from clinical trials showing that microdoses produce these same network-level shifts. The assumption that tiny doses create a milder version of the same brain-connectivity changes remains unproven.
Common Protocols and Doses
Most people who microdose follow a schedule with built-in off days, partly to prevent tolerance from building up and partly to allow time for any neuroplastic effects to consolidate. The most widely used approach is the Fadiman Protocol, named after psychologist James Fadiman: one dosing day followed by two days off, repeated in a cycle. So you might dose on Monday, skip Tuesday and Wednesday, dose again on Thursday, and so on.
A typical microdose of psilocybin mushrooms falls in the range of 0.1 to 0.3 grams of dried mushrooms. For LSD, most people report using between 5 and 20 micrograms, compared to a full recreational dose of 100 to 200 micrograms. The defining feature of a microdose is that it should be sub-perceptual. If you notice visual changes, feel emotionally altered in an obvious way, or have difficulty concentrating on normal tasks, the dose is too high. A properly calibrated microdose should feel subtle enough that you could go about your workday without anyone noticing, including yourself for much of the day.
Does It Actually Work, or Is It Placebo?
This is the central question, and the honest answer is that the science hasn’t settled it yet. Controlled studies do find that microdoses of LSD and psilocybin produce measurable changes in neurobiology, physiology, and cognition compared to placebo. But the picture gets muddier when you look at the subjective benefits people care about most, like improved mood and sharper thinking.
One large and influential study used a clever “self-blinding” design: participants prepared their own doses and placebos, shuffled them so they didn’t know which was which, then followed a four-week microdosing regimen while reporting their experiences. The result was striking. There was little difference between the placebo and real microdose conditions. Participants’ guesses about whether they had taken a real dose or a placebo had a strong influence on how they felt, and a separate study found that wellbeing outcomes were predicted by microdosers’ expectations going in.
Blinding is a persistent problem in this research. Out of 19 controlled studies reviewed, 12 assessed whether participants could tell if they were getting a real dose or placebo, and 11 of those found that participants broke blind at rates higher than chance. When people can sense even a subtle difference, the placebo effect becomes very hard to separate from genuine pharmacological effects.
That said, researchers have outlined several reasons why dismissing microdosing as “just placebo” may be premature. The number of controlled studies is still small, sample sizes have been limited, the doses used may have been too low to produce effects, and most studies have only looked at healthy volunteers rather than people with clinical depression or anxiety. The measured impact of expectancy, while real, has also been relatively small in magnitude. The honest takeaway is that microdosing sits in scientific limbo: the biology is plausible, but the clinical evidence hasn’t caught up.
A Safety Concern Worth Knowing About
One risk that rarely comes up in popular discussions of microdosing involves the heart. Both LSD and psilocybin don’t just bind to the 5-HT2A receptor that produces their psychological effects. They also bind strongly to a different serotonin receptor, 5-HT2B, which is highly expressed on cells in the heart valves. Sustained stimulation of this receptor is the established mechanism behind drug-induced heart valve disease, a condition where valve tissue thickens and stops functioning properly.
Drugs previously linked to heart valve damage tend to bind to this receptor with an affinity below a certain threshold (measured as a Ki value below 15 nanomolar). LSD’s binding affinity at this receptor is 0.98 nM, and psilocin (the active form of psilocybin) comes in at 4.6 nM, both well below that threshold. Psilocin actually shows greater affinity for the heart valve receptor than for the 5-HT2A receptor responsible for its psychological effects, meaning it likely stimulates heart valve cells at any psychoactive dose.
There is converging evidence that stimulation of this receptor over several months can lead to fibrotic changes in heart tissue, even if the substance isn’t taken daily. This doesn’t mean microdosing will cause heart problems, but the theoretical risk is grounded in well-understood pharmacology rather than speculation. Duration of use appears to be a major factor. For someone microdosing once or twice a week for months or years, this is a consideration that hasn’t been adequately studied in humans.
What the Experience Looks Like in Practice
People who microdose typically describe the effects as subtle and cumulative rather than immediate and dramatic. On dosing days, commonly reported experiences include a slight lift in mood, a sense of being more present or engaged, and mildly enhanced pattern recognition or creative thinking. These aren’t psychedelic experiences. There are no visuals, no altered sense of time, no emotional intensity beyond the normal range. If any of those show up, the dose is too high.
Many people report that the benefits become more noticeable on off days and after several weeks of consistent practice, which is consistent with the neuroplasticity hypothesis: if microdoses are gradually promoting new neural connections, the effects would build over time rather than appearing and disappearing with each dose. Whether this reflects genuine biological change or a growing expectation effect remains an open question, and it’s likely some combination of both.